new glp 1 agonist novo nordisk GLP-1s for Alzheimer's: announces trial conclusion 1,207 Glp 1 Agonist Royalty-Free

Discontinuation should be considered if appetite suppression or weight stabilization does not occur after 34 months at higher doses

We have found a significant and clinically meaningful reduction in ICP in the treatment arm as compared to the placebo arm both acutely and after 12 weeks of dosing

KnopFKVilsbllTHjbergPVLarsenSMadsbadSVlundAet al

Integration of GLP-1RAs with Guideline-directed Medical Therapy and the Management of Other Comorbidities A key practical question is how to integrate GLP-1RAs with existing therapies for HFpEF and its common comorbidities

This is a metabolic benefit that is linked to better signs of heart and liver health